Lorus and BioVectra sign pancreatic cancer drug deal

January 2005
PharmaWatch: Biotechnology;January 2005, Vol. 4 Issue 1, p14
Market Research Report
Reports on the commercial supply agreement between Lorus Therapeutics Inc. and BioVectra DCL company for pancreatic cancer candidate Virulizin. Completion of the technology transfer process to BioVectra; Evaluation on the use of Virulizin as a treatment of advanced pancreatic cancer in combination with gemcitabine; Statement of CEO Jim Wright regarding the supply agreement.


Related Articles

  • R&D Update -- Other Cancers.  // PharmaWatch: Cancer;March 2003, Vol. 2 Issue 3, p11 

    Reports developments in research and development related to cancer treatment as of February 2003. Approval of the Data Safety Monitoring Board to the continuation of the thymitaq liver cancer trial of Eximias Pharmaceutical Corp.; Expansion of the renal cell carcinoma trial of Lorus Therapeutics...

  • LORUS SIGNS VIRULIZIN SUPPLY PACT WITH BIOVECTRA.  // Worldwide Biotech;Jan2005, Vol. 17 Issue 1, p4 

    Reports on the commercial supply agreement signed by Lorus Therapeutics Inc. with Diagnostic Chemicals Limited, operating as BioVectra dcl for the commercial manufacture of Virulizin. Information on BioVectra; Number of patients enrolled for the clinical trial of Virulizin; Background of Lorus.

  • Lorus signs cancer pact with Sumitomo and Koken.  // PharmaWatch: Cancer;May 2005, Vol. 4 Issue 5, p17 

    Reports that Lorus Therapeutics Inc. has signed a collaboration agreement with Sumitomo Pharmaceuticals Co. and Koken for the development of cancer drug, Thioredoxin. Terms of the agreement; Use of Thioredoxin; Comments of the Lorus CEO, Jim Wright regarding on their collaboration with the...

  • FDA APPROVES LORUS/NCI GTI-2040 PHASE II CLINICAL TRIAL.  // Worldwide Biotech;Oct2003, Vol. 15 Issue 10, p1 

    Reports on the announcement of Lorus Therapeutics Inc. that the U.S. Food and Drug Administration has approved the U.S. National Cancer Institute's Investigational New Drug Application to begin a Phase II clinical trial to investigate Lorus' lead antisense drug for breast cancer, as of October 2003.

  • Cyclacel acquires novel anticancer drug from Lorus Therapeutics.  // PharmaWatch: Biotechnology;November 2003, Vol. 2 Issue 11, p22 

    Reports on the acquisition of the anticancer drug CYC381 from the biotechnology firm Lorus Therapeutics Inc. by Cyclacel Ltd. Ability of the drug to arrest cancer cells; Terms of the agreement; Payment received by Lorus from the agreement.

  • Lorus to advance its anticancer drug, GTI-2501 into phase II clinical trial.  // PharmaWatch: Cancer;July 2003, Vol. 2 Issue 7, p26 

    Announces the plan of Lorus Therapeutics to advance its antisense, anticancer drug, GTI-2501 into a phase II clinical trial for the treatment of advanced metastatic prostate cancer, in the fall of 2003. Mechanism of action of GTI-2501 observed during preclinical investigations.

  • Decisions Update.  // PharmaWatch: Biotechnology;Jun2005, Vol. 4 Issue 6, p12 

    The article presents several updates related to new drug applications addressed to the U.S. Food and Drug Administration. Genentech Inc.'s new drug application to start a phase 1 clinical trial of a Curis Inc. co-developed drug for basal cell carcinoma has been approved. Medarex Inc. was granted...

  • Lorus wins patent for new leukemia drug.  // PharmaWatch: Cancer;Sep2008, Vol. 7 Issue 9, p8 

    The article reports on the patent issued by the U.S. Patent and Trademark Office to Lorus Therapeutics Inc.'s clinical-stage anticancer drug LOR-2040. It reveals that the patent protects the drug from being used in treating leukemia, along with chemotherapy drugs as well as solid cancers. The...

  • LORUS' VIRULIZIN EFFECTIVE AGAINST PANCREATIC TUMORS.  // Worldwide Biotech;Jan2001, Vol. 13 Issue 1, p2 

    Reports that the anti-cancer drug Virulizin from Lorus Therapeutics Inc. has demonstrated strong anti-tumor activity in mice containing human pancreatic tumor cells, which are resistant to gemcitabine.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics